- Home
- CBRE vs BDX Comparison
CBRE vs BDX Comparison
Compare CBRE & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBRE | BDX |
|---|---|---|
| Founded | 1906 | 1897 |
| Country | United States | United States |
| Employees | 44000 | N/A |
| Industry | Real Estate | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.5B | 48.2B |
| IPO Year | 2001 | 1998 |
Fundamental Metrics
Financial Performance| Metric | CBRE | BDX |
|---|---|---|
| Price | $131.69 | $199.00 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 15 |
| Target Price | $178.58 | ★ $194.08 |
| AVG Volume (30 Days) | ★ 1.6M | 1.4M |
| Earning Date | 10-22-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 2.16% |
| EPS Growth | ★ 22.61 | N/A |
| EPS | ★ 1.77 | 1.59 |
| Revenue | ★ $40,550,000,000.00 | $21,840,000,000.00 |
| Revenue This Year | $16.05 | N/A |
| Revenue Next Year | $10.89 | $2.39 |
| P/E Ratio | ★ $75.83 | $122.40 |
| Revenue Growth | ★ 13.37 | 8.24 |
| 52 Week Low | $121.69 | $140.11 |
| 52 Week High | $174.27 | $213.08 |
Technical Indicators
Market Signals| Indicator | CBRE | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 45.55 | 71.12 |
| Support Level | $126.02 | $195.63 |
| Resistance Level | $138.11 | $211.18 |
| Average True Range (ATR) | 4.19 | 4.20 |
| MACD | 0.82 | 1.36 |
| Stochastic Oscillator | 53.96 | 98.45 |
Price Performance
Historical ComparisonAbout CBRE CBRE Group Inc
CBRE Group provides a wide range of real estate services to owners, occupants, and investors worldwide, including leasing, property and project management, and capital markets advisory. CBRE's investment management arm managed over $155 billion (at year-end 2025) for clients across diverse public and private real estate strategies.
About BDX Becton Dickinson and Company
Following the separation of the life science segment, Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.